US Medical Innovations

Executive Summary

US Medical Innovations (USMI) is a San Diego-based private company developing plasma and advanced therapeutic devices for cancer treatment. The company's proprietary technology targets cancer cells selectively while sparing healthy tissue, addressing a critical need in oncology. Founded in 2009, USMI is currently in Phase 1 development, focusing on proof-of-concept studies for its plasma-based cancer therapeutics. The approach has the potential to offer a non-invasive, targeted alternative to conventional therapies, which often cause significant side effects. Given the early stage, the company faces typical development risks including regulatory hurdles, clinical trial outcomes, and funding needs. However, the novel mechanism and promising preclinical data could position USMI as a leader in the emerging field of cold atmospheric plasma oncology. The company remains privately held with no disclosed funding rounds, indicating a lean operation that may require partnerships or capital raises to advance its pipeline. The next 12-24 months will be critical for demonstrating clinical proof of concept and securing strategic collaborations.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 Clinical Trial Results for Lead Plasma Device40% success
• Q3 2026Strategic Partnership or Licensing Agreement25% success
• Q2 2026FDA Investigational Device Exemption (IDE) Approval for Next Indication50% success